This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $158.34 in the latest trading session, marking a +1.18% move from the prior day.
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $154.14 in the latest trading session, marking a +0.62% move from the prior day.
Top Analyst Reports for Johnson & Johnson, NVIDIA & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NVIDIA Corporation (NVDA) and Cisco Systems, Inc. (CSCO).
Novavax (NVAX) Initiates Phase III Study on COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) initiates phase III study on its coronavirus vaccine, NVX-CoV2373, in the United States and Mexico.
FATE Surges More Than 152% in Three Months: Here's Why?
by Zacks Equity Research
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
by Zacks Equity Research
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Johnson & Johnson (JNJ) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $152.72, marking a -0.2% move from the previous day.
J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug
by Zacks Equity Research
J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.
J&J (JNJ) Coronavirus Vaccine Candidate Study Fully Enrolled
by Zacks Equity Research
Johnson & Johnson (JNJ) phase III study on its experimental COVID-19 single-dose vaccine candidate is now fully enrolled.
Stock Market News for Dec 18, 2020
by Zacks Equity Research
Wall Street closed at record high levels on Thursday buoyed by market participants' expectations for the Congressional approval of a fresh round of fiscal stimulus this year.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod
by Kinjel Shah
FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $153.10, moving +1.02% from the previous trading session.